Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Parallel-Group Study to Evaluate the Efficacy and Tolerability of Two Dosing Regimens of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Next Previous
Trial Profile

A Randomized Parallel-Group Study to Evaluate the Efficacy and Tolerability of Two Dosing Regimens of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deuruxolitinib (Primary)
  • Indications Alopecia areata
  • Focus Therapeutic Use
  • Sponsors Concert Pharmaceuticals

Most Recent Events

  • 06 Aug 2020 According to a Concert Pharmaceuticals media release, results was published by American Academy of Dermatology (AAD)
  • 24 Feb 2020 According to an Concert Pharmaceuticals media release, results from this study have been selected for an oral presentation at the Late-Breaking Research Program during the 2020 American Academy of Dermatology (AAD) Annual Meeting.
  • 19 Dec 2019 According to a Concert Pharmaceuticals media release, data from the Companys Phase 2 trials will support an end of Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to review and discuss the Companys registration pathway for CTP-543 for the treatment of alopecia areata. The Company expects to meet with the FDA and initiate Phase 3 testing in 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top